Pernix Therapeutics Holdings (AMEX: PTX) reported earnings on Aug. 14. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended June 30 (Q2), Pernix Therapeutics Holdings missed estimates on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped and GAAP earnings per share shrank to a loss.
Margins contracted across the board.
Pernix Therapeutics Holdings chalked up revenue of $10.5 million. The five analysts polled by S&P Capital IQ anticipated a top line of $10.7 million on the same basis. GAAP reported sales were 13% lower than the prior-year quarter's $12.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.03. The five earnings estimates compiled by S&P Capital IQ anticipated $0.00 per share. GAAP EPS were -$0.03 for Q2 compared to $0.07 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 67.5%, 870 basis points worse than the prior-year quarter. Operating margin was -13.8%, 4,250 basis points worse than the prior-year quarter. Net margin was -8.9%, 2,140 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $16.9 million. On the bottom line, the average EPS estimate is $0.04.
Next year's average estimate for revenue is $71.1 million. The average EPS estimate is $0.25.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pernix Therapeutics Holdings is buy, with an average price target of $14.40.
- Add Pernix Therapeutics Holdings to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.